Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

Background. A prospective Phase II clinical trial was conducted to assess the clinical activity of a pharmacokinetically guided suramin regimen in patients who had documented progression of metastatic prostate cancer after hydrocortisone plus antecedent or simultaneous withdrawal of flutamide.

[1]  J. Buckner,et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.

[2]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[3]  S. Steinberg,et al.  Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. , 1994, Journal of the National Cancer Institute.

[4]  D. Jodrell,et al.  Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Koutsilieris,et al.  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.

[6]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Jodrell,et al.  Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial , 1993 .

[8]  H. Scher.  Suramin: here to stay!? , 1993, Journal of the National Cancer Institute.

[9]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Scher,et al.  Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.

[11]  M. Kan,et al.  Heparin-binding fibroblast growth factors and prostate cancer. , 1993, Advances in experimental medicine and biology.

[12]  D. Jodrell,et al.  Suramin, an active drug for prostate cancer: interim observations in a phase I trial. , 1993, Journal of the National Cancer Institute.

[13]  M. R. Cooper,et al.  Adaptive control with feedback strategies for suramin dosing , 1992, Clinical pharmacology and therapeutics.

[14]  S. Steinberg,et al.  Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Duchesne,et al.  Suramin and prostate cancer: the role of hydrocortisone. , 1992, European journal of cancer.

[16]  H. Scher,et al.  Use of adaptive control with feedback to individualize suramin dosing. , 1992, Cancer research.

[17]  S. Aaronson,et al.  Growth factors and cancer. , 1991, Science.

[18]  W. Linehan,et al.  Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. , 1991, The Urologic clinics of North America.

[19]  W. Linehan,et al.  Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.

[20]  M. Dalakas,et al.  Suramin‐induced polyneuropathy , 1990, Neurology.

[21]  L. Denis,et al.  Suramin for prostatic cancer: a phase I/II study in advanced extensively pretreated disease. , 1990, European journal of cancer.

[22]  J. Supko,et al.  A Rapid Isocratic HPLC Assay of Suramin (NSC 34936) in Human Plasma , 1990 .

[23]  N. Quarto,et al.  Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin , 1989, The Journal of cell biology.

[24]  S. Shain,et al.  Differences in responsiveness of clonally derived AXC/SSh rat prostate cancer cells to secreted or prototypic mitogens. , 1989, Cancer research.

[25]  I. Tannock,et al.  Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Stein,et al.  Suramin: an anticancer drug with a unique mechanism of action. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. Robertson,et al.  The inhibition of human adrenal steroidogenic enzyme activities by suramin. , 1989, The Journal of clinical endocrinology and metabolism.

[28]  A. Palestine,et al.  Suramin keratopathy. , 1988, American journal of ophthalmology-glaucoma.

[29]  R. Coffey,et al.  Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells , 1987, Journal of cellular physiology.

[30]  E. Gelmann,et al.  Suramin and function of the adrenal cortex. , 1986, Annals of internal medicine.

[31]  J. Golden.  Pulmonary disease in the acquired immunodeficiency syndrome. , 1986, Annals of internal medicine.

[32]  R. Wittes,et al.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Hosang.  Suramin binds to platelet‐derived growth factor and inhibits its biological activity , 1985, Journal of cellular biochemistry.

[34]  M. Lavin,et al.  Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. , 1984, The Journal of biological chemistry.

[35]  E. Clercq.  Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses , 1979 .

[36]  F. Hawking.  Suramin: with special reference to onchocerciasis. , 1978, Advances in pharmacology and chemotherapy.

[37]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[38]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[39]  E. Humphreys,et al.  Degeneration of the adrenal cortex produced by germanin. , 1941, The American journal of pathology.